Biogen Inc. (BIIB) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General
Biogen Inc. (BIIB) Profile & Business Summary
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Key Information
| Ticker | BIIB |
|---|---|
| Leadership | Christopher A. Viehbacher |
| Exchange | NASDAQ |
| Official Site | https://www.biogen.com |
Market Trend Overview for BIIB
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
This model looks at how prices behave over time to describe the current market environment. It focuses on whether price is moving steadily, stalling, or losing momentum, and checks both short-term and weekly trends for confirmation. The goal is not to predict exact prices, but to help understand when conditions are supportive, risky, or unclear.
Current Market Context (Short-Term)
As of 2026-02-06 (ET), BIIB is moving sideways. Price at 201.18 is below its previous support. The next support is near 174.53, while resistance is around 210.18. View Support & Resistance from Options
Why the market looks this way?
Prices have moved back and forth over recent sessions without making steady progress. Trend signals have changed frequently, which suggests the market is stuck in a range. In this environment, chasing moves in either direction is less reliable.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-02-06 (ET)
As of 2026-02-06, BIIB is breaking down after a failed trend. Over the longer term, the trend remains bullish.
BIIB last closed at 201.18. The price is about 4.1 ATR above its recent average price (186.38), and the market is currently in a breakdown after a failed trend.
The prior trend has broken down. Downside risk is higher, and the market may need time to stabilize before a new direction forms.
Trend score: 20 out of 100. Overall alignment is weak. The market is currently in a breakdown following a failed trend. Trend alignment is weak, and recent signals suggest the structure may be breaking down.
Price is far from its recent average (about 4.1 ATR away). Chasing the move at this level carries a higher risk of a pullback.
A key resistance level is near 188.22. Price would need to move back above this level for conditions to start stabilizing.
On 2026-02-06, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-02-04] Moderate participation supported a steady price advance.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
Short Interest & Covering Risk for BIIB
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 50%)
Structure Analysis
BIIB Short positioning looks normal. Current days to cover is 2.6 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves.
Bull Trap Structural Risk
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
In the latest reporting period, short interest continues to increase. Price is consolidating near highs with a weak upward bias, appearing strong on the surface but structurally more fragile. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-01-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.